Arcellx
Latest round
- Series C
Last raised
- Mar 2021
Total raised
- $137M
Investors
- 22
About Arcellx
Arcellx, Inc. is a US-based biotechnology company focused on developing innovative cell therapies targeting cancer and autoimmune diseases, utilizing proprietary technology to enhance treatment precision and efficacy. Founded in 2014 and headquartered in Gaithersburg, US, Arcellx, Inc. specializes in biopharmaceuticals aimed at treating cancer and autoimmune diseases. David Hilbert, the CEO and founder, has been instrumental in the company's strategic direction since its inception. In February 2026, Gilead Sciences, Inc. agreed to acquire Arcellx Inc.8 billion. Arcellx specializes in innovative cell therapies targeting cancer and autoimmune diseases, leveraging its proprietary D-Domain technology in conjunction with its ddCAR and ARC-SparX platforms. These core offerings aim to enhance the efficacy of cancer treatment by enabling precise targeting and destruction of malignant cells. The therapies are in various stages of clinical development, addressing significant unmet medical needs in oncology, particularly for relapsed and refractory conditions, and are designed for multiple cancer types, including multiple myeloma.38 mn. The company generates revenue through partnerships and collaborations with healthcare institutions and pharmaceutical companies, structured around clinical trial agreements and supply arrangements. The company aims to initiate a Phase 1 study in acute myeloid leukemia (AML) within 2022, reflecting its commitment to expanding its therapeutic offerings. Furthermore, Arcellx is exploring opportunities for market expansion, particularly targeting regions in Europe and North America for broader access to its innovative therapies.
Who invested in Arcellx
22 investors across 2 rounds
See all investors in Arcellx
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Arcellx
Who invested in Arcellx?
Arcellx has 22 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Arcellx raised?
Arcellx has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Arcellx last raise money?
Arcellx's most recent round on record is a Series C, in Mar 2021.
What does Arcellx do?
Arcellx is a biotechnology company.
Where is Arcellx headquartered?
Arcellx is headquartered in Rockville, US.
Which VCs invest in companies like Arcellx?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Arcellx's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Arcellx? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.